Searchable abstracts of presentations at key conferences in endocrinology

ea0077op4.2 | Metabolism, Obesity and Diabetes | SFEBES2021

3 mg Liraglutide ameliorates inflammation and improves hypothalamic regulation of energy homeostasis by modulation of Sphingosine-1-Phosphate signalling in super-responders

Spencer Lewis , Dimitriadis Georgios K , Duggirala Aparna , Bate Danielle , Davasgaium Allan , Al-Hasani Wiaam , D Miras Alexander , Le Roux Carel , Vincent Royce P , Randeva Harpal S , Tripathi Gyanendra

Background: Growing evidence suggests that hypothalamic lipid sensing plays a key role in controlling food intake, fat deposition and energy balance and that its dysregulation could lead to obesity and type 2 diabetes (T2D). Recent investigations reported that sphingosine-1-phosphate (S1P) is involved in the hypothalamic control of energy homeostasis. Intra-cerebroventricular administration of S1P decreased food intake and increased energy expenditure in rodents.<p class="...

ea0070aep374 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Liraglutide downregulates the expression of miRNA-424 in patients with obesity

Dimitriadis Georgios K , Dimitri Federica , Bate Danielle , Leca Bianca , Davasgaium Allan , Tripathi Gyanendra , Miras Alexander D , Rubino Francesco , Christian Mark , Randeva Harpal S

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways...

ea0070aep799 | Reproductive and Developmental Endocrinology | ECE2020

Investigation of the mechanism of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovarian syndrome. the DOMINO multicentre randomised controlled trial

Dimitriadis Georgios K. , Kaur Vasha , Pérez-Pevida Belen , Bansi Davinder , Jayasena Channa , Bate Danielle , Fielding Barbara , Balfoussia Danai , Webber Lisa , Miao Yun , Mears Frederick , Jackson Nicola , Coppin Lucy , Johnson Brett , Umpleby Margot , Randeva Harpal S , Miras Alexander D

Introduction: Duodenal mucosal resurfacing (DMR) is a novel therapy for T2DM. It involves the hydrothermal ablation of up to 14 cm of the duodenal mucosa through a specially designed endoscopic catheter. The procedure is performed under general anaesthesia, patients are discharged the same day and it does not involve the implantation of a foreign body. Cohort studies have demonstrated that DMR induces meaningful hbA1c reductions of 0.9–1.4% by 3 months that are largely m...